Size | Price | Stock | Qty |
---|---|---|---|
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Purity: ≥98%
Zileuton (also known as A-64077; Abbott 64077; ZYFLO; ZYFLO CR) is a novel, potent and orally bioactive inhibitor of 5-lipoxygenase, and thus inhibits leukotrienes (LTB4, LTC4, LTD4, and LTE4) formation, it was introduced in 1996 to decrease the symptoms of asthma. Zileuton suppresses PG biosynthesis by interference with arachidonic acid (AA) release in macrophages. Zileuton significantly reduces PGE2 and 6-keto prostaglandin F1α (PGF1α) levels in activated mouse peritoneal macrophages and in J774 macrophages. Zileuton inhibits PGE2 production in LPS-stimulated human whole blood and suppresses PGE2 and 6-keto PGF1α pleural levels in rat carrageenan-induced pleurisy.
ln Vitro |
As the duration of incubation increases, IL-2 levels in zileuton-treated and untreated anti-CD3 cells drop. Zileuton probably lowers IL-2 levels by blocking 5-lipoxygenase, which in turn causes the synthesis of leukotriene B4, an IL-2 inducer[2].
|
||
---|---|---|---|
ln Vivo |
The group exhibits a considerably reduced level of NF-κB staining, and zileuton (5 mg/kg, po) treated I/R rats show that zileuton's impact to reduce NF-κB expression does not change significantly in the presence of COX inhibitors. When administered intraperitoneally (5 mg/kg), zileuton dramatically reduces the apoptotic index in I/R rats. With regard to the elevated serum TNF-α levels in the I/R group, zileuton shows no discernible effect[1]. Zileuton (1,200 mg/kg) prevents the colon and small intestine of APCΔ468 from forming polyps. Treatment with zileuton decreases the rates of non-epithelial cell proliferation in polyps and raises the rates of apoptosis in rat polyps. Both in the colon and small intestine, the number of apoptotic cells in Zileuton-treated cells has significantly increased. In Zileuton-fed APCΔ468 mice, polyposis may be greatly reduced in the small intestine and colon due to the reduced proliferation rate[3].
|
||
Animal Protocol |
|
||
References |
[1]. Abueid L, et al. Inhibition of 5-lipoxygenase by zileuton in a rat model of myocardial infarction. Anatol J Cardiol. 2016 Nov 10
[2]. Kuvibidila S, et al. Hydroxyurea and Zileuton Differentially Modulate Cell Proliferation and Interleukin-2 Secretion by Murine Spleen Cells: Possible Implication on the Immune Function and Risk of Pain Crisis in Patients with Sickle Cell Disease. Ochsner [3]. Gounaris E, et al. Zileuton, 5-lipoxygenase inhibitor, acts as a chemopreventive agent in intestinal polyposis, by modulating polyp and systemic inflammation. PLoS One. 2015 Mar 6;10(3):e0121402 |
Molecular Formula |
C11H12N2O2S
|
---|---|
Molecular Weight |
236.29
|
CAS # |
111406-87-2
|
Related CAS # |
Zileuton sodium;118569-21-4;Zileuton-d4;1189878-76-9
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
O=C(N)N(C(C1=CC2=CC=CC=C2S1)C)O
|
InChi Key |
MWLSOWXNZPKENC-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C11H12N2O2S/c1-7(13(15)11(12)14)10-6-8-4-2-3-5-9(8)16-10/h2-7,15H,1H3,(H2,12,14)
|
Chemical Name |
1-(1-(benzo[b]thiophen-2-yl)ethyl)-1-hydroxyurea
|
Synonyms |
A64077; A-64077; A64077; A 64077; trade name ZYFLO; ZYFLO CR.
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 10 mg/mL (42.32 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 100.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 10 mg/mL (42.32 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 100.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 10 mg/mL (42.32 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 4.2321 mL | 21.1604 mL | 42.3209 mL | |
5 mM | 0.8464 mL | 4.2321 mL | 8.4642 mL | |
10 mM | 0.4232 mL | 2.1160 mL | 4.2321 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT01130688 | TERMINATED | Drug: Zileuton | Chronic Myelogenous Leukemia | University of Massachusetts,Worcester | 2010-01 | Phase 1 |
NCT01136941 | COMPLETED | Drug: Zileuton | Sickle Cell Disease | Children's Hospital Medical Center, Cincinnati |
2010-09 | Phase 1 |
NCT00534625 | COMPLETED | Drug:zileuton Drug:placebo |
Asthma | Critical Therapeutics | 2007-09 | Phase 2 |
NCT04996199 | UNKNOWN STATUS | Drug:Oxcarbazepine Drug:Carbamazepine |
Trigeminal Neuralgia | Postgraduate Institute of Dental Sciences Rohtak |
2021-09-18 | Phase 4 |
NCT00595114 | COMPLETED | Asthma Pulmonary Disease,Chronic Obstructive |
Brigham and Women's Hospital | 2007-12 |
Concentration of interleukin-2 (IL-2) in the supernatant of (A and B) concanavalin A (ConA)-treated and (C and D) anti-CD3 antibody–treated murine spleen cells incubated without and with either hydroxyurea (HU) or zileuton for 12-48 h. Values are means ± SEM, n=11. With each mitogen and incubation period, bars followed by different letters are significantly different: a>b>c, P<0.05. FCS, fetal calf serum.Ochsner J . 2015 Fall;15(3):241-7. td> |
Effects of incubation time and treatment of hydroxyurea and zileuton on interleukin-2 (IL-2) secretion by (A) concanavalin A (ConA)-treated and (B) anti-CD3 antibody–treated murine spleen cells. Values are means ± SEM, n=11. With each drug, bars with different letters are significantly different: a>b>c, P<0.05. FCS, fetal calf serum.Ochsner J . 2015 Fall;15(3):241-7. td> |
3H-thymidine incorporation into DNA in mitogen-treated and untreated murine spleen cells incubated without and with hydroxyurea (HU) or zileuton in (A) 2% fetal calf serum (FCS)- and (B) 5% FCS-supplemented culture medium. Values are means ± SEM, n=11. Bars with different letters are significantly different: a>b, P<0.05. ConA, concanavalin A; PHA, phytohemagglutinin.Ochsner J . 2015 Fall;15(3):241-7. td> |